Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does erlotinib improve symptoms in patients with lung cancer?

Nature Clinical Practice Oncology volume 4, pages 146–147 (2007)Cite this article

boxed-textBezjak A et al. (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 24: 3831–3837

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Silvestri G et al. (1998) Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. Br Med J 317: 771–775

    Article  Google Scholar 

  2. Shepherd FA et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132

    Article  Google Scholar 

  3. Aaronson NK et al. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365–376

    Article  Google Scholar 

  4. Bergman B et al. (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 30A: 635–642

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. DM Jackman is an Instructor in Medicine and PA Jänne is an Assistant Professor of Medicine at Harvard Medical School in Boston, MA. Both are medical oncologists in the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, Boston, MA, USA.,

    David M Jackman & Pasi A Jänne

Authors
  1. David M Jackman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pasi A Jänne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pasi A Jänne.

Ethics declarations

Competing interests

DM Jackman has received honoraria from both Genentech and Roche, although both fall under the de minimus (<$10,000 per year) as prescribed by Partners Health Systems and Harvard University.

PA Jänne has received an unrestricted grant (>$100,000) from Genentech. He is also part of a pending patent application for epidermal growth factor receptor (EGFR) mutation testing.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jackman, D., Jänne, P. Does erlotinib improve symptoms in patients with lung cancer?. Nat Rev Clin Oncol 4, 146–147 (2007). https://doi.org/10.1038/ncponc0738

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0738

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing